References

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.14412/1995-4484-2009-1310

rsp-1192

Research Article

Статьи

Articles

Стандарты терапии псориатического артрита

Standards of therapy of psoriatic arthritis

Коротаева

Т. В.

Korotaeva

T V

Насонов

Евгений Львович

Nasonov

E L

2009

15062009

473

№3 (2009)

2937

2009

Коротаева Т.В., Насонов Е.Л.

Korotaeva T.V., Nasonov E.L.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/1192

Псориатический артрит (ПсА) – хроническое воспалительное заболевание суставов, позвоночника и энтезисов из группы серонегативных спондилоартритов, обычно ассоциированное с псориазом [1]. Считают, что заболевание возникает в результате сложных взаимодействий между генетическими, иммунологическими и внешнесредовыми факторами.

References1

<div>Moll J. M. H., Wright V. Psoriatic arthritis. Semin. Arthritis Rheum., 1973,3,55–78.Melski J. W., Bernhard J. D., Stern R. S. The Koebner (isomorphic) response in psotiasis. Associations with early at onset and multiple previous therapies. Arch. Dermatol., 1983,119, 655-9.Scarpa R., Del Puente A., di Girolamo C. et аl. Interplay between environmental factors, articular involvement, and HLA-B27 in patients with psoriatic arthritis. Ann. Rheum. Dis., 1999,51, 78-9.Langevitz P., Buskila D., Gladman D. D. Psoriatic Arthritis precipitated by physical trauma. J. Rheumatology, 2006,33(7),1417-56.Punzi L., Pianon M., Bertazzolo N. et al. Clinical, laboratory and immunogenetic aspects of post-traumatic psoriatic arthritis: A study of 25 patients. Clin. Exp. Rheumatol., 1998, 16, 277-81.Bruce I. N., Silman A. J. The aetiology of psoriatic arthritis. Rheumatology (Oxford), 2001,40, 363-6.Rasmussen J. E. The relationship between infection with group A hemolytic streptococci and the development. Pediatr. Inf. Dis., J. 2000,19,153-4.Rahman M.U., Ahmed S., Schumacher H. R. et al. High levels of antipeptidoglycan antibodies in psoriatic and other seronegative arthritides. J. Rheumatology,1990,17,621-5.Asumalahti K., Veal C., Laitinen T. et.al. Coding Haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum. Mol. Genet., 2002,11,589-97.Gladman D.D., Farewell V.T. The role of HLA antigens as psoriatic arthritis indicators of progression in psoriatic arthritis (PsA); multivariate relative risk model. Arthritis Rheum., 1995,25,730-3.Gonzalez S., Martinez-Borra J., Torre-Alonso J. C. et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the associationof Cw*0602 in psoriasis. Arthritis Rheum., 1999,42,1010-6.Hohler T., Kruger A., Schneider P. M. et.al. A TNF- alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J. Invest. Dermatol., 1997,109, 562-5.Cassel S., Kavanaugh A. Psoriatic Arthritis: Pathogenesis and novel immunomodulatory approaches to treatment. J. Imm. Bas. Ther. Vaccines, 2005,3,6- 9.Ritchlin C. Pathogenesis of Psoriatic Arthritis. Curr. Opin. Rheum., 2005,17, 406-12.Mease P. J. Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann. Rheum. Dis., 2002, 61, 298-304.Reece R. J., Canete J. D., Parsons W. J. et al. Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum., 1999, 42(7), 1481-4.Fearon U., Griosiose K., Fraser A. et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J. Rheumatology, 2003, 30, 260-8.Peters R. Vascular endothelial growth factor and the angiopoietins. Working together to build a better blood vessel. Circul. Res., 1998, 83, 342-3.Fearon U., Reece R.J., Blythe D. et al. Synovial cytokine and growth factor regulation of MMPs/ TIMPs: implication for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann. N. Y. Acad. Sci., 1999,872, 619-21.Creamer D.J., Jaggar R., Allen M. et al. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br. J. Dermatol., 1997, 137, 851-5.Kuroda K.S., Sapadin A., Shoji T. et al. Altered expres- sion of angiopoietins and Tie 2 endothelium receptor in psoriasis. J. Inves. Dermatol., 2001,116(5), 713-20.Canete J., Pablos J., Sanmarti R. et al. Antiangiogenic effect of anti-Tumor Necrosis Factor α therapy with Infliximab in psotiatic arthritis. Arthritis Rheum., 2004, 50(5), 1636-41.Cordiali-Fei P., Trento E., D,Agosto G. et al. Effective therapy with anti-TNF-α in psotiatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann. N. Y. Acad. Sci., 2007, 1110, 578-89. 35Fraser A. D., van Kuijk A.W., Westhovens R. et al. A randomized, double blind, placebo controlled, multicentre triale of combination therapy with methotrexate plus cyclosporine in patients with active psotiatic arthritis. Ann. Rheum. Dis., 2005, 64, 859-64.Moll J. M. H., Wright V. Psoriatic arthritis. Semin. Arthritis Rheum., 1973, 3, 55–78.Mease P. J., Helliwell P. S. (Editors). Atlas of Psoriatic Arthritis. Springer (London) 2008, 118.Тaylor W., Gladman D., Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum., 2006,54, 2665–73.Chandran V., Schentag C., Gladman D. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum., 2007, 57(8), 1560-63Oliveri I., Barozzi L., Favaro L. et al. Dactilitis in patients with seronegative spondylarthropathy. Assesment by ultrasonograhy and magnetic resonance imaging. Arthritis Rheum., 1996, 39, 1524–8.Kane D., Greaney T., Bresnihan B. et. al. Ultrasonography in the diagnosis and manegment of psoriatic dactilitis. J. Rheumatology, 1999, 26, 1746- 51.Healy P., Helliwell Ph. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum., 2008, 5(59), 686–91.MgGonald D., Gibbon W., Emery P. Classification of inflammatory arthritis.by enthesitis. Lancet, 1998, 352, 1137-40.Salonen D. C., Brower A. C. et al. Seronegative spon- dyloarthropathies: imaging. Edited by Hochberg M. C., Silman A. J., Smolen J. S. Philadelphia: Mosby, 2003, 1193-204.Khan M., Schentag C., Gladman D. D. Clinical and radiological changes during psoriatic arthritis disease progression. J. Rheumatology, 2003, 30, 1022-26.Veale D., Rogers S., Fitzgerald O. Classification of subset in psoriatic arthritis. Br. J. Rheumatol., 1994, 33, 133-8.Gladman D. D, Shuckett R., Russell M.L. et.al. Psoriatic arthritis – clinical and laboratory analysis of patients. Q. J. Med., 1987, 62, 127-41.Lambert J. R., Wright V. Eye inflammation in psoriatic arthritis. Ann. Rheum. Dis., 1976, 35, 354-6.Queiro R., Torre J. C., Belzunegui J. et. al. Clinical features and predictive factors in psoriatic arthritis uveitis. Semin. Arthritis Rheum., 2002, 31, 264-70.Wong K., Gladman D. D., Husted J., et. al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic 1. Causes and risk of death. Arthritis Rheum., 1997, 40, 1868–72.Cantini F., Niccoli L., Nannini C. et al. Frequency and duration of clinical remission in patients with peripherial psoriatic arthritis requiring second-line drugs. Rheumatol., 2008, 9, 1-5. 36 41.Ritchlin C. T. Therapies for psoriatic enthesopathy. A systematic review. J. Rheumatology, 2006, 33, 1435- 8.Stafford L., Kane D., Murphy E. et al. Psoriasis predicts a poor short-term outcome in patients with spondyloarthropathy Arthritis Care Res., 2001, 45, 485-93.Kavanaugh A., Ritchlin C. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Systematic Review of Treatments of Psoriatic Arthritis. J. Rheumatology, 2006, 33 (7), 1417-56.Kyle S., Chandler D., Griffiths C. E. et al. Guideline for anti-TNF-α in psoriatic arthritis. Rheumatol., 2005, 44, 390-7.Tukriewicz A., Moreland L. Psoriatic Arthritis. Current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum., 2007, 56(4), 1051-66.Gottlieb A., Korman N., Gordon K. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J. Am. Acad. Dermatol., 2008, 58(5), 851- 64.Soriano E., McHugh N. Therapies for perepheral joint disease in psoriatic arthritis. A systematic Review. J. Rheumatology, 2006, 33,1-7.Sarzi-Puttini P., Santandrea S., Boccasini L. et. al. The role of NSADI in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin. Exper. Rheumatol., 2001, 19, suppl 22, S17-S20.Lassus A. A. A comparative pilot study of azapropa- zone and indomethacin in the treatment of psoriatic arthritis and Reiter,s disease. Curr. Med. Res. Opin., 1976, 4, 65-9.Lonauer G., Wirth W. Controlled double blind study on the effectiveness and adverse effects of acemetacin and indomethacin in the treatment of psoriatic arthri- tis. Arzneimittelforshung 1980, 30, 1440-4.Leathham P. A., Bird H. A., Wright V. et al. The run-in period in trial design: a comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy. Agent. Actions., 1982,12, 221-4.Hopkins R., Bird H. A., Jones H. et al. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann. Rheum. Dis., 1985, 44,189- 93.Powles A. V., Griffiths C. E., Seifert M. H. et al. Exacerbation of psoriasis by indomethacin. Br. J. Dermatol., 1987, 117, 799-800.Pipitоne N., Kingsley G. H., Manzo A. et al. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatol., (Oxford), 2003, 42, 1138-48.Gladman D. D., Farewell V. T., Nadeau C. Clinical indicators of progression on psoriatic arthritis: multivariate relative risk model. J. Rheumatology, 1995, 22, 675-9.Cleg D.O., Reda D. J., Mejias E. et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis patients. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum., 1996, 39, 2013- 20.Gupta A. K., Grober J. S., Hamilton T. A. et al. Sulfasalazine therapy for psoriatic arthritis: a double blind placebo controlled trial. J. Rheumatology, 1995, 22, 894-8.Combe B., Goupille P., Hamilton T. A. et al. Sulfasalazine in psoriatic arthritis: a randomized, multicenter, placebo – controlled study. Br. J. Rheum., 1996, 35, 664-8.Rahman P., Gladman D. D., Cook R. J. et al. The use of sulfasalszine in psoriatic arthritis: clinical experience. J. Rheumatology, 1998, 18, 27-33.Salvarani C., Macchioni P., Olivieri I. et al. A Comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J. Rheumatology, 2001, 28, 2274-82.Willkens R. F., Williams H. J., Ward J. R. Randomized, double blind placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum., 1984, 27, 376-81.Gladman D. D., Strand V., Mease P. et. al. OMERACT psoriatic arthritis workshop: synopsis. Ann. Rheum. Dis., 2005, 64, (suppl 2), ii115-6.Jones G., Grotty M., Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review), In the Cochrane Library, issue 2, 2004; Oxford Update Software.Zachariae H., Zachariae E. Methotrexate treatment of psoriatic arthritis. Acta. Derm. Venerol., 1987, 67, 270-3.Espinoza L. R., Zakraoui L., Espinoza L. R. Psoriatic arthritis: clinical response and side effects to Methotrexate therapy. J. Rheumatology, 1992, 19, 872-7.Abu-Shakra M., Gladman D. D., Thorne J. C. et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J. Rheumatology, 1995, 22, 241-5.Fraser A. D., van Kuijk A. W. R., Westhovens R. et al. A randomized, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann. Rheum. Dis., 2005, 64, 859-64.Kaltwasser J. P., Nash P., Gladman D. D. et al. Treatment of psoriatic arthritis study group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multionational, double- blind, randomized, placebo – controlled clinical trial. Arthritis Rheum., 2004, 50, 1939-50.Cuchacovich M., Soto L. Leflunomide decreases joint erosion and induces reparative changes in a patients with psoriatic arthritis. Ann. Rheum. Dis., 2001, 60, 913-23.Sparado A., Riccieri V., Sili-Scavalli A. et al. A Comparison of cyclosporine and methotrexate in the treatment of psoriatic arthritis: a one – year prospective study. Clin. Exp. Rheum., 1995,13, 589-93.Macchioni P., Boiardi L., Cremonesi T. et al. The relationship between serum-soluble interleuikin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporine-A. Rheum. Int., 1998, 18, 27-33.Ravindran V., Scott D.L., Choy E. H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann. Rheum. Dis., 2008, 67, 855-9.Salvarani C., Oliveri I., Pipitone N. et al. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF- α blocking) agents in the treatment in psoriatic arthritis of pso- riatic arthritis. Clin. Exp. Rheum., 2006, 24, 70-8.Etanercept and infliximab for the treatment of adults with psoriatic arthritis. N. H. S, 2007.Sattar N., Crompton Ph., Cherry L. et al. Effects of Tumor Necrosis Factor Blocade on Cardiovascular Risk Factor in Psoriatic arthritis. A double-blind, placebo–controlled Study. Arthritis Rheum., 2007, 56(3), 831-9.Canete J., Pablos J., Sanmarti R. et al. Antiangiogenic Effects of Anti-Tumor Necrosis Factor Therapy With Infliximab in Psoriatic arthritis. Arthritis Rheum., 2004, 50(5), 1636-41.Cordiali-Fei P., Trento E., D’Agosto G. et al. Effective therapy with anti-TNF-alpha in psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann. N. Y. Acad. Sci., 2007, 1110, 578-89.Antoni C., Kavanaugh A., Kirkhan B. et al. Sustained benefits of infliximab therapy for dermatological and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 2005, 52, 1227-36.Antoni C., Krueger G.G., de Vlam K. et al. IMPACT Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT Trial. Ann. Rheum. Dis., 2005, 64, 1150-7.Mease P., Gladman D., Ritchlin C. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum., 2005, 52(10), 3279-89.Gladman D., Mease P., Rithlin Ch. et al. Adalimumab for Long-Term Treatment of Psoriatic Arthritis. Forty- Eight Week Data From the Adalimumab Effectiveness in Psoriatic ArthritisTrial. Arthritis Rheum., 2007, 56(2), 476-88.Gladman D., Mease P., Rithlin Ch. et al. Adalimumab improves joint-and skin-related functional impairment in patients with psoriatic arthritis: Patients-reported outcomes of the Adalimumab Effectiveness in psoriatic arthritis trials (ADEPT). Ann. Rheum. Dis., 2006, 9, 1-6.McHugh N., Van den Bosch F., Manger B. et al. Adalimumab (Humira®) Treatment is Effective in patients with Psoriatic Arthritis (PsA) in Day-to-Day Clinical Practice – Results From the STEREO Trial. 6th Ann. General Meeting of the British Society for Rheumatology (BSR), UK, Liverpool, 2008, abs 259.Mease P. J., Thomson G., Klinkhoff A. et al. Psoriatic arthritis patients receiving Adalimumab (Humira®) sustain improvements in health – related quality of life (HRQOL) 144-week results, 9th Annual European League Against Rheumatism, June 11-14, 2008; Paris, France, SAT 0449.Mease P. J., Ory P., Sharp J. T. et al. Adalimumab (Humira®) sustains inhibition of joint damage for more than 2 years in patients with Psoriatic Arthritis (PsA), 9th Annual European League Against Rheumatism, June 11-14, 2008, Paris, France, OP-0163.Van den Bosch F., Manger B., Goupille P. et al. Clinical remission in patients with Psoriatic Arthritis (PsA) treated with Adalimumab (Humira®). Results of the Stereo trial. 6th Biennial International Congress on Spondyloarthropathies; October 2-4, 2008; Ghent, Belgium. Abstract P70.Furst D. E., Keystone E. C, Kirkham B., et al. Updeted consensus statement on biological agents for the treat- ment of rheumatic diseases, 2008. Ann. Rheum. Dis., 2008, 67(Suppl. 3), iii2-iii25.</div>

The authors declare that there are no conflicts of interest present.